Loading
A breast and gynaecologic oncologist deeply involved in the early trastuzumab deruxtecan studies and in Japanese ADC development.
Kan Yonemori is Chief of the Department of Medical Oncology at the National Cancer Center Hospital in Tokyo. A breast and gynaecologic oncologist, he was deeply involved in the early studies of trastuzumab deruxtecan and in Japanese antibody-drug conjugate development, serving as an investigator on the DESTINY-Breast trials. His publications include the phase 1 dose-escalation study of trastuzumab deruxtecan in advanced breast and gastric tumours, a phase 1/2 trial of the HER3-directed conjugate patritumab deruxtecan in metastatic breast cancer, and the long-term analysis of DESTINY-Breast03 comparing trastuzumab deruxtecan with trastuzumab emtansine. He leads medical oncology across breast, gynaecologic and sarcoma indications.
Shares National Cancer Center Hospital, Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
Shares National Cancer Center Hospital, Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
Shares Trastuzumab deruxtecan, HER2-positive breast cancer, Antibody-drug conjugate (ADC), HR-positive / HER2-negative breast cancer.
Shares Trastuzumab deruxtecan, HER2-positive breast cancer, Antibody-drug conjugate (ADC), HR-positive / HER2-negative breast cancer.
Shares DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer, Trastuzumab deruxtecan, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
Shares Trastuzumab deruxtecan, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
Shares Trastuzumab deruxtecan, Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Trastuzumab deruxtecan, HER2-positive breast cancer, Antibody-drug conjugate (ADC).